Trial reportScience translational medicine2019
Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species.
Open access · bronzeAbstract readClinical Trial
In one paragraph
Trial report in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 48 citations in OpenAlex.
- Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TCFrontiers in immunology · 2023Trial
- Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.PLoS pathogens · 2022Trial
- Enhancing the Sensitivity of Mass Spectrometry Imaging through Spatial Signal Averaging.Journal of the American Society for Mass Spectrometry · 2026Article
- Human immunodeficiency virus-associated gut microbiome impacts systemic immunodeficiency and susceptibility to opportunistic gut infection.Nature microbiology · 2026Article
- Context dependency is essential for predicting intrahost evolution.Nature ecology & evolution · 2026Article
- Enhancing antiretroviral delivery to secondary lymph nodes by targeting CD169 + macrophages with HIV-mimicking nanoparticles.Scientific reports · 2025Article
- A TCR-mimic bispecific antibody reduces HIV-1 provirus and delays viral rebound in HLA-matched humanized mice.bioRxiv : the preprint server for biology · 2025Article
- Heterogeneous Antiretroviral Drug Exposure in Male and Female Genital Tract Tissues.The Journal of infectious diseases · 2025Article
- Mapping the Gut Microbiota Composition in the Context of Raltegravir, Dolutegravir, and Bictegravir-A Scoping Review.International journal of molecular sciences · 2025Article
- The Future of Gene Expression Studies in HIV Research.Current HIV research · 2025Review
- Review
- Application of infrared matrix-assisted laser desorption electrospray ionization mass spectrometry for morphine imaging in brain tissue.Analytical and bioanalytical chemistry · 2023Article
- The development and application of matrix assisted laser desorption electrospray ionization: The teenage years.Mass spectrometry reviews · 2023Review
- Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques.Frontiers in immunology · 2023Article
- Mass spectrometry imaging: new eyes on natural products for drug research and development.Acta pharmacologica Sinica · 2022Review
- Pharmacological Validation of Long-Term Treatment with Antiretroviral Drugs in a Model of SIV-Infected Non-Human Primates.Pharmaceutics · 2022Article
- Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates.Antimicrobial agents and chemotherapy · 2022Article
- TheiScience · 2022Article
- Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.Scientific reports · 2022Article
- Increased biomarkers of cardiovascular risk in HIV-1 viremic controllers and low persistent inflammation in elite controllers and art-suppressed individuals.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 1 country.
Corbin G ThompsonDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-2559-1030
Elias P RosenDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5531-7281
Heather M A PrinceSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nicole WhiteDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-5741-8008
Craig SykesDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gabriela de la CruzDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-6019-5853
Michelle MathewsDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Claire DeleageAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.ORCID 0000-0002-3507-0055
Jacob D EstesAIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD, USA.
Paige CharlinsDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Leila R MulderDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-2998-9292
Martina KovarovaDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lourdes AdamsonDepartment of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.
Shifali AroraSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-1556-1882
Evan S DellonSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-1167-1101
Anne F PeerySchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nicholas J ShaheenSchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-6602-5647
Cynthia GaySchool of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David C MuddimanW.M. Keck FTMS Laboratory for Human Health Research, Department of Chemistry, North Carolina State University, Raleigh, NC, USA.ORCID 0000-0003-2216-499X
Ramesh AkkinaDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
J Victor GarciaDivision of Infectious Diseases, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Paul LuciwDepartment of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA.
Angela D M KashubaDivision of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. akashuba@unc.edu.ORCID 0000-0002-9171-8493
University of North Carolina at Chapel Hill · USColorado State University · USLeidos (United States) · USUniversity of California, Davis · USNC Department of Health and Human Services · US
Funding
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MNovel Mass Spectrometry Imaging Methods to Quantify Antiretroviral AdherenceR01AI122319 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KASHUBA, ANGELA D, ROSEN, ELIAS · 2016 to 2021
$5.3MMulti-Species Mechanisms of Drug Bio-distribution in HIV Tissue ReservoirsR01AI111891 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KASHUBA, ANGELA D · 2014 to 2018
$4.3MCCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI111891NIAID NIH HHS R01 AI122319
Abstract
HIV replication within tissues may increase in response to a reduced exposure to antiretroviral drugs. Traditional approaches to measuring drug concentrations in tissues are unable to characterize a heterogeneous drug distribution. Here, we used mass spectrometry imaging (MSI) to visualize the distribution of six HIV antiretroviral drugs in gut tissue sections from three species (two strains of humanized mice, macaques, and humans). We measured drug concentrations in proximity to CD3
Indexed as
AdolescentAdultAgedAnimalsAnti-Retroviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1CD3 ComplexFemaleGastrointestinal TractGene Expression Regulation, ViralHIVHumansMacaca mulattaMaleMiceMiddle AgedAnti-Retroviral AgentsATP Binding Cassette Transporter, Subfamily B, Member 1CD3 ComplexRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.